Biocept reports first quarter 2022 financial results

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended march 31, 2022 and provides a business update. “net revenues for the first quarter increased 12% to $19.9 million, driven by rt-pcr covid-19 testing services,” said samuel d. riccitelli, biocept's chairman, and interim president and ceo. “we continued to generate strong growth with our proprietary neuro-oncology
BIOC Ratings Summary
BIOC Quant Ranking